Who are Hyperpolarized 13C,15N2-urea's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tc99m sestamibi, Preoperative Injection of Carbon Nanoparticles, Intraoperative Injection of Carbon Nanoparticles, 123I-meta-iodobenzylguanidine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/hyperpolarized-13c-15n2-urea.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Hyperpolarized 13C,15N2-urea — Competitive Intelligence Brief

Hyperpolarized 13C,15N2-urea (Hyperpolarized 13C,15N2-urea) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Diagnostic imaging agent. Area: Oncology.

phase 2 Diagnostic imaging agent Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Hyperpolarized 13C,15N2-urea (Hyperpolarized 13C,15N2-urea) — Ivan de Kouchkovsky, MD. Hyperpolarized 13C,15N2-urea is a diagnostic imaging agent that uses hyperpolarized carbon-13 to enhance the visibility of metabolic processes in the body.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Hyperpolarized 13C,15N2-urea TARGET	Hyperpolarized 13C,15N2-urea	Ivan de Kouchkovsky, MD	phase 2	Diagnostic imaging agent
Tc99m sestamibi	Tc99m sestamibi	M.D. Anderson Cancer Center	marketed	Radiotracer / Diagnostic imaging agent	Mitochondrial membrane potential
Preoperative Injection of Carbon Nanoparticles	Preoperative Injection of Carbon Nanoparticles	Second Affiliated Hospital of Xi'an Jiaotong University	phase 3	Diagnostic imaging agent / Surgical tracer
Intraoperative Injection of Carbon Nanoparticles	Intraoperative Injection of Carbon Nanoparticles	Second Affiliated Hospital of Xi'an Jiaotong University	phase 3	Diagnostic imaging agent / Surgical tracer
123I-meta-iodobenzylguanidine	123I-meta-iodobenzylguanidine	Vancouver Coastal Health	phase 3	Radiopharmaceutical; diagnostic imaging agent	Norepinephrine transporter (NET)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Diagnostic imaging agent class)

Ivan de Kouchkovsky, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hyperpolarized 13C,15N2-urea — Competitive Intelligence Brief. https://druglandscape.com/ci/hyperpolarized-13c-15n2-urea. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab